Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index

Adrian S Dobs, Paul Norwood, Susan Potts, Errol Gould, Surya Chitra

Research output: Contribution to journalArticle

Abstract

Introduction: Little is known about the effect of body mass index (BMI) on the efficacy and safety of testosterone therapy in hypogonadal men. A prior noncomparative trial demonstrated that testosterone 2% gel restored testosterone levels in hypogonadal men and was generally well tolerated. Aim: This post hoc analysis evaluated the influence of BMI on the pharmacokinetics of testosterone therapy in men with low testosterone. Methods: Men (N=149) aged 18-75 applied testosterone 2% gel to the front and inner thigh once daily for 90 days. Starting dose was 40mg/day, which could be adjusted at days 14, 35, and 60. Patients were split into categories depending on baseline BMI: Tertile 1 (≤29.1kg/m2), Tertile 2 (29.2-32.4kg/m2), and Tertile 3 (>32.4kg/m2). Main Outcome Measures: Efficacy end points were average serum total testosterone concentrations over 24 hours and maximum serum testosterone concentrations at day 90. Adverse events were recorded. Results: The efficacy analysis included 129 men with low testosterone (mean age 52.9, 54.0, and 54.2 years for Tertiles 1, 2, and 3, respectively) defined as serum testosterone <250-300ng/dL. Baseline testosterone levels were comparable across BMI tertiles. After 90 days of treatment with testosterone 2% gel (≥40mg/day), 79.1%, 79.5%, and 73.8% of patients in Tertiles 1, 2, and 3, respectively, achieved serum testosterone concentrations in the physiologic range (i.e., ≥300 to ≤1,140ng/dL). The mean average daily dose at day 90 was higher in participants in Tertiles 3 vs. 2 (P=0.039) and Tertiles 3 vs. 1 (P=0.010). The gel was generally well tolerated, with skin reactions the most commonly reported adverse event (16.1%; n=24). Conclusions: In this study, daily application of testosterone 2% gel was effective at returning serum testosterone to physiologic levels in men with low testosterone and high BMI, although required dose was affected by BMI.

Original languageEnglish (US)
Pages (from-to)857-864
Number of pages8
JournalJournal of Sexual Medicine
Volume11
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Testosterone
Body Mass Index
Gels
Serum
Thigh
Therapeutics
Pharmacokinetics
Outcome Assessment (Health Care)

Keywords

  • Body Mass Index
  • Hypogonadism
  • Testosterone Replacement
  • Transdermal Systemic Testosterone Gel

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology
  • Urology

Cite this

Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index. / Dobs, Adrian S; Norwood, Paul; Potts, Susan; Gould, Errol; Chitra, Surya.

In: Journal of Sexual Medicine, Vol. 11, No. 3, 01.01.2014, p. 857-864.

Research output: Contribution to journalArticle

Dobs, Adrian S ; Norwood, Paul ; Potts, Susan ; Gould, Errol ; Chitra, Surya. / Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index. In: Journal of Sexual Medicine. 2014 ; Vol. 11, No. 3. pp. 857-864.
@article{b3aa820ee40f46d2a063c99b17543750,
title = "Testosterone 2{\%} gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index",
abstract = "Introduction: Little is known about the effect of body mass index (BMI) on the efficacy and safety of testosterone therapy in hypogonadal men. A prior noncomparative trial demonstrated that testosterone 2{\%} gel restored testosterone levels in hypogonadal men and was generally well tolerated. Aim: This post hoc analysis evaluated the influence of BMI on the pharmacokinetics of testosterone therapy in men with low testosterone. Methods: Men (N=149) aged 18-75 applied testosterone 2{\%} gel to the front and inner thigh once daily for 90 days. Starting dose was 40mg/day, which could be adjusted at days 14, 35, and 60. Patients were split into categories depending on baseline BMI: Tertile 1 (≤29.1kg/m2), Tertile 2 (29.2-32.4kg/m2), and Tertile 3 (>32.4kg/m2). Main Outcome Measures: Efficacy end points were average serum total testosterone concentrations over 24 hours and maximum serum testosterone concentrations at day 90. Adverse events were recorded. Results: The efficacy analysis included 129 men with low testosterone (mean age 52.9, 54.0, and 54.2 years for Tertiles 1, 2, and 3, respectively) defined as serum testosterone <250-300ng/dL. Baseline testosterone levels were comparable across BMI tertiles. After 90 days of treatment with testosterone 2{\%} gel (≥40mg/day), 79.1{\%}, 79.5{\%}, and 73.8{\%} of patients in Tertiles 1, 2, and 3, respectively, achieved serum testosterone concentrations in the physiologic range (i.e., ≥300 to ≤1,140ng/dL). The mean average daily dose at day 90 was higher in participants in Tertiles 3 vs. 2 (P=0.039) and Tertiles 3 vs. 1 (P=0.010). The gel was generally well tolerated, with skin reactions the most commonly reported adverse event (16.1{\%}; n=24). Conclusions: In this study, daily application of testosterone 2{\%} gel was effective at returning serum testosterone to physiologic levels in men with low testosterone and high BMI, although required dose was affected by BMI.",
keywords = "Body Mass Index, Hypogonadism, Testosterone Replacement, Transdermal Systemic Testosterone Gel",
author = "Dobs, {Adrian S} and Paul Norwood and Susan Potts and Errol Gould and Surya Chitra",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/jsm.12411",
language = "English (US)",
volume = "11",
pages = "857--864",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index

AU - Dobs, Adrian S

AU - Norwood, Paul

AU - Potts, Susan

AU - Gould, Errol

AU - Chitra, Surya

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Introduction: Little is known about the effect of body mass index (BMI) on the efficacy and safety of testosterone therapy in hypogonadal men. A prior noncomparative trial demonstrated that testosterone 2% gel restored testosterone levels in hypogonadal men and was generally well tolerated. Aim: This post hoc analysis evaluated the influence of BMI on the pharmacokinetics of testosterone therapy in men with low testosterone. Methods: Men (N=149) aged 18-75 applied testosterone 2% gel to the front and inner thigh once daily for 90 days. Starting dose was 40mg/day, which could be adjusted at days 14, 35, and 60. Patients were split into categories depending on baseline BMI: Tertile 1 (≤29.1kg/m2), Tertile 2 (29.2-32.4kg/m2), and Tertile 3 (>32.4kg/m2). Main Outcome Measures: Efficacy end points were average serum total testosterone concentrations over 24 hours and maximum serum testosterone concentrations at day 90. Adverse events were recorded. Results: The efficacy analysis included 129 men with low testosterone (mean age 52.9, 54.0, and 54.2 years for Tertiles 1, 2, and 3, respectively) defined as serum testosterone <250-300ng/dL. Baseline testosterone levels were comparable across BMI tertiles. After 90 days of treatment with testosterone 2% gel (≥40mg/day), 79.1%, 79.5%, and 73.8% of patients in Tertiles 1, 2, and 3, respectively, achieved serum testosterone concentrations in the physiologic range (i.e., ≥300 to ≤1,140ng/dL). The mean average daily dose at day 90 was higher in participants in Tertiles 3 vs. 2 (P=0.039) and Tertiles 3 vs. 1 (P=0.010). The gel was generally well tolerated, with skin reactions the most commonly reported adverse event (16.1%; n=24). Conclusions: In this study, daily application of testosterone 2% gel was effective at returning serum testosterone to physiologic levels in men with low testosterone and high BMI, although required dose was affected by BMI.

AB - Introduction: Little is known about the effect of body mass index (BMI) on the efficacy and safety of testosterone therapy in hypogonadal men. A prior noncomparative trial demonstrated that testosterone 2% gel restored testosterone levels in hypogonadal men and was generally well tolerated. Aim: This post hoc analysis evaluated the influence of BMI on the pharmacokinetics of testosterone therapy in men with low testosterone. Methods: Men (N=149) aged 18-75 applied testosterone 2% gel to the front and inner thigh once daily for 90 days. Starting dose was 40mg/day, which could be adjusted at days 14, 35, and 60. Patients were split into categories depending on baseline BMI: Tertile 1 (≤29.1kg/m2), Tertile 2 (29.2-32.4kg/m2), and Tertile 3 (>32.4kg/m2). Main Outcome Measures: Efficacy end points were average serum total testosterone concentrations over 24 hours and maximum serum testosterone concentrations at day 90. Adverse events were recorded. Results: The efficacy analysis included 129 men with low testosterone (mean age 52.9, 54.0, and 54.2 years for Tertiles 1, 2, and 3, respectively) defined as serum testosterone <250-300ng/dL. Baseline testosterone levels were comparable across BMI tertiles. After 90 days of treatment with testosterone 2% gel (≥40mg/day), 79.1%, 79.5%, and 73.8% of patients in Tertiles 1, 2, and 3, respectively, achieved serum testosterone concentrations in the physiologic range (i.e., ≥300 to ≤1,140ng/dL). The mean average daily dose at day 90 was higher in participants in Tertiles 3 vs. 2 (P=0.039) and Tertiles 3 vs. 1 (P=0.010). The gel was generally well tolerated, with skin reactions the most commonly reported adverse event (16.1%; n=24). Conclusions: In this study, daily application of testosterone 2% gel was effective at returning serum testosterone to physiologic levels in men with low testosterone and high BMI, although required dose was affected by BMI.

KW - Body Mass Index

KW - Hypogonadism

KW - Testosterone Replacement

KW - Transdermal Systemic Testosterone Gel

UR - http://www.scopus.com/inward/record.url?scp=84895448794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895448794&partnerID=8YFLogxK

U2 - 10.1111/jsm.12411

DO - 10.1111/jsm.12411

M3 - Article

C2 - 24283410

AN - SCOPUS:84895448794

VL - 11

SP - 857

EP - 864

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 3

ER -